An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
- 29 May 2008
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 22 (12) , 2269-2272
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaBlood, 2007
- Current and emerging treatment options in chronic myeloid leukemiaCancer, 2007
- Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activationBlood, 2006
- The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 2006
- Germline KRAS mutations cause Noonan syndromeNature Genetics, 2006
- Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemiaNature Reviews Cancer, 2005
- Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majorityBlood, 2003
- BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood, 2003
- Wild-Type p53 Induces Diverse Effects in 32D Cells Expressing Different OncogenesMolecular and Cellular Biology, 1996